All In Biotech

Drug Trial Radar · NCT04764851

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

A Phase 1, Open-Label, Fixed Sequence Drug-Drug Interaction Study to Evaluate the Effects of Repeat Doses of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

30

Actual

Start

Feb 18, 2021

Primary completion

Apr 2, 2021

Study completion May 7, 2021

Sponsor

Lead sponsor
Emalex Biosciences Inc.Industry
Sponsor type
Industry
Collaborators
Syneos Health; Nuventra, Inc.
First posted
Feb 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.

Conditions

  • Drug-Interactions

Interventions

  • ecopipam HCl ~2mg/kg/dayDrug

    oral tablet

  • Cohort 1 Probe CocktailCombination product

    dextromethorphan, caffeine, omeprazole, and midazolam

  • Cohort 2 Probe CocktailCombination product

    dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam

  • Cohort 3 Probe CocktailCombination product

    bupropion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of dextromethorphan (and its dextrorphan metabolite) in the presence of ecopipamTime frame: Up to Day 18
  2. Cmax of dextromethorphan (and its dextrorphan metabolite) in the absence of ecopipamTime frame: Up to Day 18
  3. Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
  4. Cmax of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
  5. Cmax of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
  6. Cmax oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
  7. Cmax of dabigatran in the presence of ecopipamTime frame: Up to Day 18
  8. Cmax of dabigatran in the absence of ecopipamTime frame: Up to Day 18
  9. Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 18
  10. Cmax of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 18
  11. Cmax of rosuvastatin in the presence of ecopipamTime frame: Up to Day 18
  12. Cmax of rosuvastatin in the absence of ecopipamTime frame: Up to Day 18
  13. Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 18
  14. Cmax of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 18
  15. AUCinf of dextromethorphan (and its dextrorphan metabolite) in the presence of ecopipamTime frame: Up to Day 18
  16. AUCinf of dextromethorphan (and its dextrorphan metabolite) in the absence of ecopipamTime frame: Up to Day 18
  17. AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
  18. AUCinf of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
  19. AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
  20. AUCinf of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
  21. AUCinf of dabigatran in the presence of ecopipamTime frame: Up to Day 18
  22. AUCinf of dabigatran in the absence of ecopipamTime frame: Up to Day 18
  23. AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 18
  24. AUCinf of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 18
  25. AUCinf of rosuvastatin in the presence of ecopipamTime frame: Up to Day 18
  26. AUCinf of rosuvastatin in the absence of ecopipamTime frame: Up to Day 18
  27. AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 18
  28. AUCinf of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 18
  29. AUClast of dextromethorphan (and its dextrorphan metabolite) in the presence of ecopipamTime frame: Up to Day 18
  30. AUClast of dextromethorphan (and its dextrorphan metabolite) in the absence of ecopipamTime frame: Up to Day 18
  31. AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
  32. AUClast of IV midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
  33. AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the presence of ecopipamTime frame: Up to Day 18
  34. AUClast of oral midazolam (and its 1'-hydroxymidazolam metabolite) in the absence of ecopipamTime frame: Up to Day 18
  35. AUClast of dabigatran in the presence of ecopipamTime frame: Up to Day 18
  36. AUClast of dabigatran in the absence of ecopipamTime frame: Up to Day 18
  37. AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the presence of ecopipamTime frame: Up to Day 18
  38. AUClast of pitavastatin (and its pitavastatin lactone metabolite) in the absence of ecopipamTime frame: Up to Day 18
  39. AUClast of rosuvastatin in the presence of ecopipamTime frame: Up to Day 18
  40. AUClast of rosuvastatin in the absence of ecopipamTime frame: Up to Day 18
  41. AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the presence of ecopipamTime frame: Up to Day 18
  42. AUClast of atorvastatin (and its 4'-hydroxy atorvastatin metabolite) in the absence of ecopipamTime frame: Up to Day 18

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Syneos Health Clinical Research Services, LLC.

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.